Macrogenics
Macrogenics' revenue fell 0.3% to $150 million in fiscal 2025. Its operating margin was −48.7%, up from −73.7% a year earlier. Free cash flow was −$83 million. The diluted share count rose 0.8%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
What Macrogenics does
MacroGenics is a clinical-stage biopharmaceutical company that develops antibody-based cancer treatments. It builds its drug candidates from its own antibody technology platforms, including antibody-drug conjugates, which link an antibody to a cancer-killing drug, and multi-specific antibodies that it calls DART and TRIDENT molecules.
It has three proprietary candidates in clinical trials: lorigerlimab, MGC026 and MGC028. Three products developed with its technology have FDA approval, but it has out-licensed or sold them to partners: Zynyz, Margenza and Tzield. It keeps certain economic rights, so it can receive payments on them.
Much of its money comes from partners. Its collaborations have provided over $1.6 billion of non-dilutive funding, meaning funding that does not give up ownership. It also works with Gilead Sciences on a candidate called MGD024. It runs a commercial-scale antibody factory at its Maryland headquarters and provides contract manufacturing to partners and others to help cover the plant's costs.
Its biggest risks, as it describes them
- It will need substantial additional funding, which may not be available on acceptable terms.
- It has lost money since it began and may never be profitable.
- Drug development is long and costly, and its outcome is highly uncertain.
- Raising money could dilute owners or require it to give up rights.
Income statement
Macrogenics lost money in fiscal 2025: a net loss of $75 million.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 124 | 109 | 101 | 183 | 57 |
| Debt incl. finance leases | — | — | — | — | — |
| Net debt (negative means net cash) | — | — | — | — | — |
| Net debt to EBITDA | — | — | — | — | — |
| Debt to equity | — | — | — | — | — |
| Interest coverage | — | — | −117.7x | −99.2x | −8.6x |
| Current ratio | 3.8x | 4.6x | 4.5x | 3.9x | 5.1x |
| Quick ratio | 3.7x | 4.5x | 4.5x | 3.9x | 4.9x |
Cash flow
Projections
Project Macrogenics' revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
What Macrogenics says to expect
- Cash runway
MacroGenics anticipates that its cash, cash equivalents and marketable securities of $287.7 million as of September 30, 2026, in addition to projected and anticipated future payments from partners, will support its cash runway through 2028.
Insider trades
Over the 12 months between November 20, 2025 and November 19, 2026, no insider bought Macrogenics shares on the open market, and 1 insider sold $129,086, all of it under trading plans set up in advance.
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Aug 19, 2026 | Jeffrey Stuart PetersSenior VP, GC, and Secretary | Sold plan | 31,105 | $4.15 | $129,086 | Form 4 |
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | — | — | — |
| Rule of 40 | −197.4% | 107.2% | −55.8% |
| Altman Z'' | −10.44 | −12.52 | −12.89 |
| Accruals ratio | 23.9% | 0.5% | 2.5% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Fail | Fail |
| Cash from operations is positive | Fail | Fail | Fail |
| Return on assets rose | Pass | Fail | Fail |
| Cash from operations exceeds net income | Fail | Fail | Fail |
| Debt fell relative to assets | — | — | — |
| Current ratio rose | Fail | Fail | Pass |
| Share count didn't rise | Fail | Fail | Fail |
| Gross margin rose | Pass | Pass | Pass |
| Revenue rose relative to assets | Fail | Pass | Pass |
| F-score | — | — | — |
Compare
Put Macrogenics side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Macrogenics | FY25 | −0.3% | −48.7% | −55.5% | — | — | — | |
| Karyopharm Therapeutics | FY25 | 0.6% | −62.1% | −51.6% | — | — | 2 | Compare |
| Beam Therapeutics | FY25 | 120.0% | −274.6% | −257.6% | — | — | — | Compare |
| Regenxbio | FY25 | 104.5% | −94.6% | −74.2% | — | — | — | Compare |
| Valneva SE | FY25 | 3.0% | −47.0% | −32.8% | −34.5% | — | 1 | Compare |
10 years of figures
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | 92 | 158 | 60 | 64 | 105 | 77 | 152 | 59 | 150 | 150 |
| Revenue growth | −8.9% | 71.7% | −61.9% | 6.8% | 63.4% | −26.2% | 96.2% | −61.3% | 155.3% | −0.3% |
| Gross profit | — | — | — | 64 | 105 | 75 | 149 | 58 | 149 | 150 |
| Research and development | 122 | 147 | 191 | 195 | 193 | 215 | 207 | 167 | 177 | 147 |
| Operating income | −60 | −22 | −171 | −177 | −131 | −203 | −121 | −168 | −111 | −73 |
| Net income | −58 | −20 | −172 | −152 | −130 | −202 | −120 | −9 | −67 | −75 |
| Diluted EPS (US$) | −1.69 | −0.54 | — | −3.16 | −2.47 | −3.37 | −1.95 | −0.15 | −1.07 | −1.18 |
| Diluted shares (millions) | 35 | 36 | 41 | 48 | 52 | 60 | 61 | 62 | 63 | 63 |
| Cash flow | ||||||||||
| Cash from operations | −44 | 14 | −153 | −134 | −112 | −144 | −87 | −78 | −68 | −81 |
| Capital expenditure | 11 | 29 | 25 | 4 | 6 | 6 | 4 | 2 | 4 | 2 |
| Free cash flow | −55 | −15 | −178 | −139 | −118 | −150 | −91 | −80 | −72 | −83 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock-based compensation | 12 | 15 | 16 | 20 | 21 | 23 | 20 | 18 | 29 | 14 |
| Balance sheet at fiscal year end | ||||||||||
| Cash and short-term investments | 84 | 212 | 220 | 126 | 181 | 124 | 109 | 101 | 183 | 57 |
| Debt incl. finance leases | — | — | — | — | — | — | — | — | — | — |
| Total assets | 311 | 374 | 332 | 312 | 379 | 335 | 280 | 298 | 262 | 257 |
| Total liabilities | 42 | 75 | 89 | 82 | 83 | 96 | 138 | 146 | 146 | 201 |
| Shareholders' equity | 269 | 299 | 243 | 231 | 296 | 240 | 142 | 153 | 116 | 56 |
| Margins and ratios | ||||||||||
| Gross margin | — | — | — | 100.0% | 100.0% | 96.6% | 97.8% | 99.0% | 99.4% | 100.0% |
| Operating margin | −65.3% | −14.0% | −284.8% | −276.0% | −125.0% | −261.9% | −79.9% | −286.4% | −73.7% | −48.7% |
| Net margin | −63.7% | −12.4% | −285.2% | −236.5% | −123.7% | −261.0% | −78.8% | −15.4% | −44.7% | −49.9% |
| Free cash flow margin | −59.9% | −9.5% | −296.4% | −215.9% | −112.3% | −193.7% | −59.6% | −136.1% | −48.1% | −55.5% |
| Rule of 40 (growth + FCF margin) | −68.8% | 62.2% | −358.3% | −209.1% | −48.9% | −219.9% | 36.6% | −197.4% | 107.2% | −55.8% |
| Return on capital | — | — | — | — | — | — | — | — | — | — |
| Return on equity | −20.1% | −6.9% | −63.2% | −64.1% | −49.3% | −75.5% | −62.8% | −6.2% | −49.9% | −87.0% |
| Return on assets | −17.5% | −5.7% | −48.6% | −47.1% | −37.5% | −56.6% | −38.9% | −3.1% | −23.9% | −28.8% |
| Net debt to EBITDA | — | — | — | — | — | — | — | — | — | — |